title: Irinotecan as a new agent for urachal cancer.
abstract: The urachal carcinoma, in a 64-year-old male with multiple lung metastases, had shown the resistance to several anti-neoplastic agents including cisplatinum, methotrexate, 5-FU, doxorubicin, epirubicin, and mitomycin C. Because the tumor was adenocarcinoma producing mucin and serum carcinoembryonic antigen (CEA) increased, which resembled colorectal carcinoma, we administrated Irinotecan, which was very effective as the CEA decreased from 98.3 to 38.7 ng/ml and the pulmonary metastatic lesions were reduced by 60%. To our knowledge, this is the first case with urachal carcinoma in which Irinotecan was effective.
authors.affiliation: Department of Urology, Faculty of Medicine, University of Tokyo, and Division of Urology, Asoka Hospital, Tokyo, Japan. kume@kuc.biglobe.ne.jp
authors.forename: Haruki
authors.initials: H
authors.lastname: Kume
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Tomita
authors.forename: Sayuri
authors.initials: S
authors.lastname: Takahashi
authors.forename: Keiko
authors.initials: K
authors.lastname: Fukutani
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D014497:Urachus
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin